ARSU.F Stock Overview
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Fagron NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €20.03 |
| 52 Week High | €20.85 |
| 52 Week Low | €18.06 |
| Beta | 0.26 |
| 11 Month Change | -3.93% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 13.92% |
| 5 Year Change | n/a |
| Change since IPO | -63.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARSU.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.2% |
| 1Y | n/a | 2.1% | 31.7% |
Return vs Industry: Insufficient data to determine how ARSU.F performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how ARSU.F performed against the US Market.
Price Volatility
| ARSU.F volatility | |
|---|---|
| ARSU.F Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARSU.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ARSU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,647 | Rafael Padilla | www.fagron.com |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding.
Fagron NV Fundamentals Summary
| ARSU.F fundamental statistics | |
|---|---|
| Market cap | US$1.42b |
| Earnings (TTM) | US$81.16m |
| Revenue (TTM) | US$854.69m |
17.4x
P/E Ratio1.7x
P/S RatioIs ARSU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARSU.F income statement (TTM) | |
|---|---|
| Revenue | €820.76m |
| Cost of Revenue | €458.22m |
| Gross Profit | €362.54m |
| Other Expenses | €284.61m |
| Earnings | €77.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.07 |
| Gross Margin | 44.17% |
| Net Profit Margin | 9.50% |
| Debt/Equity Ratio | 69.2% |
How did ARSU.F perform over the long term?
See historical performance and comparison